Business

Teitur Trophics, a biotech company developing new treatments for patients suffering from neurodegenerative diseases, has complete a €28M Series A financing.   The financing was co-led by Sunstone Life Science Ventures and Sound Bioventures, with participation from new investors, Industrifonden, Innovestor’s Life Science Fund and P53 Invest. The proceeds will enable Teitur to progress its lead […]

Women in Life Science Denmark (WiLD), an inspiring and science-centric not-for-profit network for women in senior positions across industry and academia, launched in January 2023 to strengthen value creation in the Danish Life Sciences industry, while promoting talent, diversity and inclusiveness. DDW’s Megan Thomas caught up with WiLD to learn more about the future for […]

Dr John Ballantyne, co-founder of Aldevron, has invested $3 million in CureLab Oncology and CureLab Veterinary. The two sister companies have developed an anti-cancer and anti-inflammatory drug that was contract-manufactured by Aldevron at the time Dr Ballantyne served there as chief scientific officer. Both CureLab Oncology and CureLab Veterinary are developing therapies that employ plasmids […]

Biopharmaceutical subsidiary Rhythm Pharmaceuticals Netherlands has acquired Xinvento, a Netherlands-based biotech company focused on developing therapies for congenital hyperinsulinism (CHI).  CHI is a rare genetic disease in which cells secrete excess insulin, causing hypoglycemia, which can result in serious health outcomes including seizures, coma, permanent brain damage and death.   Xinvento is developing novel investigational therapeutic […]

A new strategic guide, intended to help manufacturers bring rare disease products to market, has been launched to mark Rare Disease Day (February 28). In the guide, Terebellum (a subsidiary of AscellaHealth) shares tips on how industry stakeholders can create an effective market access strategy, giving their treatment the best chance of success in a competitive […]

The Tecan Group and Oxford Nanopore Technologies will collaborate to drive easier high throughput nanopore library preparation in an automated, hands-free fashion.   The aim of the partnership is a fully automated workflow for Oxford Nanopore’s Ligation Sequencing Kit XL V14 protocol (LSK114) with Tecan’s DreamPrep NGS solutions.  The LSK114 protocol allows for any fragment length […]

Under a new agreement, Destiny Pharma and Sebela Pharmaceuticals will co-develop NTCD-M3, Destiny’s lead asset for the prevention of Clostridioides difficile infection (CDI) recurrence.  It is anticipated that Sebela will lead and finance the future clinical development and commercialisation activities of NTCD-M3 in North America.   Destiny will keep most rights for Europe and Rest of […]

Spanish pharma company Ferrer and Swiss biotech Asceneuron have signed a licensing agreement giving Ferrer the rights to ASN90 in progressive supranuclear palsy (PSP), an orphan, tau-related disease with a high unmet medical need.  The terms of the agreement include an upfront fee and multiple development, regulatory and commercial milestone payments. Asceneuron is also eligible […]

Kristina Tatiossian, PhD, founder of Arkitekt Agency, looks at how biotech companies are currently using social media and provides a five-step guide for how to make the most of this ubiquitous marketing tool. Biotechnology organisations can leverage social media for a variety of purposes, from boosting awareness and increasing engagement, to connecting with stakeholders and […]

Cerevance has expanded its Series B funding round with an additional close of $51 million, bringing the total to $116 million.  The financing will support upcoming clinical trials focused on Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), and schizophrenia.   “We are thrilled to secure additional funding from world-class investors who strongly support the need for novel […]